Full-Time

Business Development Executive

Posted on 10/31/2025

Singular Genomics

Singular Genomics

51-200 employees

Sells high-throughput genomic sequencing platforms

Compensation Overview

$130.2k - $190k/yr

+ Bonus + Commission + Equity

United States

Hybrid

Category
Business & Strategy (1)
Requirements
  • 5–10+ years of experience in life science tools, genomics, or molecular diagnostics sales.
  • Proven success in closing high-value deals with pharma, biotech, or academic medical centers.
  • Strong technical acumen in genomics, spatial biology, or single-cell analysis.
  • Excellent communication, negotiation, and executive presence.
  • Ability to travel 30–50%.
  • Bachelor’s degree in Life Sciences; advanced degree (MS, PhD, MBA) a plus.
Responsibilities
  • Identify, develop, and close new business opportunities in the Midwest territory.
  • Build and manage relationships with key stakeholders in biopharma, academic centers, CROs, and research hospitals.
  • Navigate complex sales cycles involving scientific, technical, and procurement stakeholders.
  • Deliver compelling value propositions aligned to customer workflows and research priorities.
  • Manage forecasting, territory planning, and CRM tracking.
  • Collaborate with Field Applications, Marketing, and Executive teams to drive strategic deals and early access deployments.
  • Represent the company at key regional meetings, trade shows, and networking events.
Desired Qualifications
  • Experience selling novel platforms or disruptive life science technologies
  • Established network across East Coast translational and clinical research sites
  • Familiarity with spatial transcriptomics, immuno-oncology, or biomarker discovery markets

Singular Genomics provides genomic sequencing tools and consumables for researchers and clinical labs. Its G4 sequencing platform is ultra-high-throughput and processes multiple samples in parallel for DNA/RNA sequencing and multiomic analyses using flow cells and related consumables. The company emphasizes high-throughput, high-resolution spatial sequencing within a single platform and a focus on end-to-end workflows that combine the instrument and consumables to help users scale projects. Its goal is to accelerate scientific and medical research by enabling faster, larger, and more integrated genomic studies.

Company Size

51-200

Company Stage

IPO

Headquarters

San Diego, California

Founded

2016

Simplify Jobs

Simplify's Take

What believers are saying

  • John Stark's CEO appointment leverages 25 years experience from Quantum-Si and Celsee.
  • Vanderbilt Center of Excellence deploys G4X for HTAN GAME3D gastric pre-cancer atlases.
  • G4X launch on February 18, 2026, validated consistency across 1,700 samples in 50 runs.

What critics are saying

  • December 18, 2025 data breach exposes PII and biological data, triggering FTC probes.
  • 10x Genomics Visium HD captures translational budgets with superior subcellular resolution.
  • Deerfield acquisition forces Q1 2027 revenue, diluting G4X margins against NanoString CosMx.

What makes Singular Genomics unique

  • G4X Spatial Sequencer processes 128 samples and 40 sq cm per run with subcellular resolution.
  • Proprietary 4-color SBS chemistry delivers 85% bases ≥ Q30 accuracy for paired-read sequencing.
  • Four independent flow cells enable parallel running of 1-16 samples without pooling.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Performance Bonus

Company Equity

Remote Work Options

Growth & Insights and Company News

Headcount

6 month growth

1%

1 year growth

2%

2 year growth

0%
Beauregard News
Mar 18th, 2026
Singular Genomics and Vanderbilt University Medical Center establish Center of Excellence to advance high-throughput spatial multimodal profiling in Gastric Pre-Cancer.

Singular Genomics and Vanderbilt University Medical Center establish Center of Excellence to advance high-throughput spatial multimodal profiling in Gastric Pre-Cancer. PR Newswire Today at 4:45am PDT Collaboration deploys the High Throughput In Situ Multiomics capabilities of G4X(TM) to support HTAN's Pre-Gastric Cancer program and enable scalable generation of multimodal 3D atlases. SAN DIEGO and NASHVILLE, Tenn., March 18, 2026 /PRNewswire/ - Singular Genomics today announced a collaboration with Vanderbilt University Medical Center (VUMC) to establish a Center of Excellence leveraging the G4X(TM) Spatial Sequencer in support of the Human Tumor Atlas Network (HTAN) Pre-Gastric Cancer program. HTAN is an NCI-supported collaborative effort dedicated to constructing 3D atlases of the cellular, molecular, morphological, and spatial features of cancers and their microenvironments over time, including key transitions such as progression from precancer to malignancy. Scaling spatial multimodal atlas building via throughput and operational efficiency A key challenge in building high-quality spatial atlases is generating sufficiently large, standardized datasets across longitudinal and heterogeneous clinical specimens. Through this Center of Excellence, VUMC investigators will deploy G4X to support market-leading throughput, more cost-efficient spatial multimodal profiling, enabling larger cohorts, and more consistent data generation for 3D atlas-building workflows. G4X is designed to generate integrated in situ readouts at scale, combining 1,000-plex RNA, 18-plex protein, and fH&E at subcellular resolution from each FFPE tissue section at industry-leading throughput. Supporting the GAME3D Gastric Pre-Cancer Atlas VUMC is a participating institution in HTAN's Center for Gastric Pre-Cancer Atlas of Multidimensional Evolution in 3D (GAME3D). GAME3D focuses on building a comprehensive multimodal atlas spanning key transitions in gastric disease progression, with emphasis on early lesions and longitudinal sampling. The GAME3D effort aims to create a dynamic 2D spatial atlas and a 3D spatiotemporal atlas at single-cell resolution, alongside developing computational models of tumor initiation and progression. The G4X platform will serve as a core technology in this effort by enabling integrated, scalable spatial transcriptomic and proteomic profiling within a unified workflow. "HTAN programs are advancing a new generation of atlases that require both multimodal measurement and the ability to scale across meaningful cohorts," said Josh Stahl, CEO at Singular. "By partnering with Vanderbilt University Medical Center to establish this Center of Excellence, we aim to support cost-effective, standardized, and high-throughput spatial multimodal profiling that helps investigators generate the datasets needed to study early gastric cancer disease evolution." "As part of the research activities of the VUMC GAME3D HTAN team, we are pleased to collaborate with Singular Genomics to support our research focused on generating 3D spatial multimodal datasets, with findings shared through HTAN with the broader cancer research community." Stated Dr. Tae Hyun Hwang, Endowed Director in AI Research and Professor of Surgery at Vanderbilt University Medical Center Relationship to HTAN and NCI This collaboration is an institution-level partnership between Singular Genomics and Vanderbilt University Medical Center investigators supporting HTAN-branded research activities at VUMC. No endorsement by the National Cancer Institute (NCI) or the HTAN program as a whole is stated or implied. About Singular Genomics Singular is a life science technology company focused on delivering high-throughput spatial pathology solutions to advance precision medicine. The company's recently launched G4X(TM) Spatial Sequencer enables scalable, multiomic analysis directly in tissue, combining performance, throughput, and cost efficiency to support translational research, AI-driven insights, and clinical developments. Singular is headquartered in San Diego, California. About Vanderbilt University Medical Center Vanderbilt University Medical Center (VUMC), based in Nashville, Tennessee, is a comprehensive academic medical center whose core missions include patient care, the education of health care professionals, and scientific discovery, with longstanding strengths in translational research and biomedical informatics. VUMC delivers care through a broad health system and reports more than 3.2 million patient visits annually across its ambulatory locations and hospitals. About the Human Tumor Atlas Network (HTAN) The Human Tumor Atlas Network (HTAN) is an NCI-supported collaborative program constructing 3-dimensional atlases of the cellular, molecular, morphological, and spatial features of human cancers and their microenvironments over time. Launched in 2018 as part of the Cancer Moonshot initiative, HTAN brings together research centers and a data coordinating center to help characterize how cancers evolve from precancerous lesions to advanced disease. Forward-Looking Statements This press release contains forward-looking statements concerning Singular Genomics' products, partnerships, and future business plans. These statements reflect management's current expectations and are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied. Singular Genomics undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this release. SOURCE Singular Genomics This is a paid placement. For further inquiries, please contact PR Newswire directly.

PR Newswire
Feb 18th, 2026
Singular Genomics launches G4X platform with 128-sample capacity for spatial multiomics

Singular Genomics has launched the G4X platform in the US, a spatial multiomics system designed for translational research and clinical applications. The platform analyses 500-plex RNA, 18-plex protein and fH&E at subcellular resolution, processing 128 samples and 40 square centimetres per run — nearly 10 times higher throughput than competing systems. The system delivers results in five days at costs in the low hundreds per sample. Last year, G4X processed nearly 20,000 FFPE samples and profiled approximately 4 billion spatially resolved single cells. A validation study analysed 1,700 samples across 50 runs, demonstrating consistent performance. The launch follows a successful early access programme at five academic medical centres. The system is now commercially available for purchase in the United States.

San Diego Biotechnology Network
Feb 18th, 2026
Singular Genomics Launches G4X(TM) in the U.S., Delivering Industry-Leading Throughput for In Situ Multiomics, Targets Translational and Clinical Applications

Singular Genomics launches G4X(TM) in the U.S., delivering industry-leading throughput for in situ multiomics, targets translational and clinical applications. February 18, 2026 SDBN news, PR newswire, syndication comments off on Singular Genomics launches G4X(TM) in the U.S., delivering industry-leading throughput for in situ multiomics, targets translational and clinical applications. SAN DIEGO, Feb. 18, 2026 /PRNewswire/ - Singular Genomics, a company delivering high-throughput spatial technologies to advance precision medicine, today announced the commercial launch and U.S. availability of G4X. The launch marks a major milestone in making large-scale spatial...

Migliaccio & Rathod LLP
Dec 18th, 2025
Singular Genomics Data Breach Investigation

Singular Genomics Data Breach investigation. Migliaccio & Rathod LLP is investigating the possible Singular Genomics Data Breach, impacting an undetermined number of individuals and their personal information. What happened? On December 18, 2025, dark web monitoring sites reported that Singular Genomics had been named as a victim of a data breach. Little information is available yet about the nature of the breach or the information that may have been involved, but the affected information is believed to include sensitive data from clients and staff, such as personally identifiable information, financial information, and biological data. All of the information possibly stolen is likely valuable and dangerous to affected victims. As is likely to be the case with the Singular Genomics data breach, in previous cyberattacks, victims of data theft have noticed identity theft attempts ranging from fraudulent charges on bank accounts or credit cards, to unauthorized credit card applications, to medical services or government services ordered in their name, to their information being posted on the dark web, to a massive uptick in the number of spam text messages, calls and emails received. Are you concerned that you might be affected by the Singular Genomics data breach? If you have concerns that you have been affected by this data breach, and/or have experienced suspicious activity recently, Migliaccio & Rathod LLP would like to hear from you. Please complete the contact form on this page, send Migliaccio & Rathod LLP an email at [email protected], or give Migliaccio & Rathod LLP a call at (202) 470-3520. The following will ask for your contact information so that Migliaccio & Rathod LLP may reach you to talk about potential claims. This information is for its records only and will not be shared. By continuing, you consent to the collection of this information for these limited purposes. Did you receive a notification that you were affected by the data breach? Would you like to join its newsletter to receive notifications about other investigations Migliaccio & Rathod LLP is looking into, as well as updates on ongoing cases? The lawyers at Migliaccio & Rathod LLP have years of experience in class action litigation against large corporations, including in cases involving data breaches such as this. More information about its current cases and investigations is available on its blog. Data Breach FAQ. I received a notice that my information may have been involved in a data breach. What should I do? Take the notification seriously and read it carefully. It should outline what specific information was affected (e.g., name, Social Security number, legal case data). Even if you believe your risk is minimal, it's best to take proactive steps to protect yourself. Some of these recommended steps can be found listed below. What immediate actions should I take? * Monitor your financial accounts - Regularly check your bank, credit card, and online accounts for unauthorized transactions. * Change your passwords - Update passwords for any accounts that may be connected to the breach. Avoid reusing old or similar passwords. Use a password manager if needed. * Set up two-factor authentication (2FA) - Enable 2FA on your email, banking, and other sensitive accounts to add an extra layer of protection. * Place a fraud alert or credit freeze - Contact one of the three major credit bureaus (Equifax, Experian, TransUnion) to place a fraud alert or freeze your credit report. This makes it harder for someone to open new accounts in your name. What is credit monitoring, and how should I use it? Credit monitoring tracks your credit report for changes or suspicious activity. If the organization that was breached offers this service for free, it's highly recommended you enroll. These services can alert you quickly to potential fraud and help prevent further damages. How long do I need to stay vigilant? The effects of a data breach can surface months or even years later. Stay alert to signs of identity theft for at least 12 - 24 months. Keep an eye on your credit reports, mail, and any unfamiliar account activity. Who can I contact if I need help? Use the contact details provided in the breach notification. You can also report identity theft to the Federal Trade Commission at www.identitytheft.gov for recovery resources.

GlobeNewswire
Feb 21st, 2025
Singular Genomics Acquired for $20/Share

Singular Genomics Systems announced the closing of its acquisition by Deerfield Management for $20 per share in cash. The transaction, approved by shareholders on February 19, 2025, results in Singular Genomics becoming a private company. Josh Stahl is appointed CEO, with Jason Myers joining the Board. Trading of Singular's stock is suspended on Nasdaq, and delisting is requested. Drew Spaventa remains on the Board as a special advisor.

INACTIVE